Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies (NYSE: A) has declared a quarterly dividend of 24.8 cents per share of common stock. The dividend will be paid on July 23, 2025, to shareholders of record as of July 1, 2025. The company notes that future dividend amounts and timing will be subject to board approval.
Agilent Technologies (NYSE: A) has announced two significant additions to its Board of Directors: Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown, founder and CEO of Downtown Advisory, effective May 21, 2025. Soriot brings extensive pharmaceutical industry experience as AstraZeneca's CEO since 2012, while Gawlik Brown contributes substantial financial and strategic expertise from her roles at Perrigo Company and Amgen. The appointments coincide with Agilent's three-year Ignite Transformation initiative.
Simultaneously, Heidi Kunz is retiring from the Board after more than 20 years of service, having joined at the company's inception in 2000. Agilent, which generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide, continues its commitment to balanced Board refreshment.
Agilent Technologies (NYSE: A) announced that CEO Padraig McDonnell and CFO Bob McMahon will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for June 4, 2025, at 10:30 a.m. Eastern in New York City. Investors and interested parties can access a live audio webcast and replay of the presentation through the Agilent Investor Relations website.
Summary not available.
Agilent Technologies (NYSE: A) has announced its participation at the AACR Annual Meeting 2025 in Chicago, showcasing innovative cancer research solutions. The company unveiled three new Avida DNA Cancer Panels for ultra-sensitive detection of cancer genomic alterations from liquid biopsies, featuring a streamlined 5-hour workflow.
Key highlights include partnerships with Tagomics for their Interlace Multiomics assay integration with Agilent's SureSelect Cancer CGP assay, and collaboration with Roswell Park Cancer Center for the SureSelect Cancer Pan Heme Assay. Additionally, Agilent announced a strategic partnership with Abcam for IHC Companion Diagnostics development using Abcam's portfolio of over 10,000 recombinant monoclonal antibodies.
Agilent Technologies (NYSE: A) has received European IVDR certification for its PD-L1 IHC 22C3 pharmDx assay as a Companion Diagnostic (CDx) for gastric or gastroesophageal junction (GEJ) adenocarcinoma patients. The certification aids in identifying patients eligible for KEYTRUDA® therapy.
The assay is now IVDR certified for seven cancer indications, including non-small cell lung cancer, urothelial carcinoma, esophageal cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, and cervical cancer. It remains the only IVDR-certified CDx for gastric and GEJ adenocarcinoma patients seeking KEYTRUDA treatment.
This expansion is particularly significant given that gastric cancer affected over 130,000 Europeans in 2022, with a 5-year survival rate of 26% in Europe. The assay works exclusively with Agilent's Autostainer Link 48 advanced staining solution.
Agilent Technologies (NYSE: A) has scheduled the release of its second-quarter fiscal year 2025 financial results after market close on Wednesday, May 28. The company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. Investors can access the listen-only webcast through the Events section of Agilent's investor relations website, where a recording will remain available for 90 days.
Agilent Technologies (NYSE: A) has announced its contribution to the FDA approval of AUCATZYL®, a CAR T therapy developed by Autolus Therapeutics. The company's xCELLigence Real-Time Cell Analysis (RTCA) technology played a important role in developing and validating the therapy's potency assay.
The xCELLigence RTCA platform provides continuous, real-time monitoring of cell behavior without labels or dyes, using electrical impedance to measure cell numbers, viability, and morphology. This technology offers advantages over traditional endpoint assays by enabling more accurate and timely decision-making in drug development.
Agilent and Autolus will present their findings at the 2025 Hybrid US Bioassay Conference in Tucson, Arizona, discussing lessons learned in CAR T Cell Product Potency Measurement.